ShortSide Research (@ShortSideIO) header
ShortSide Research (@ShortSideIO) profile picture

Institutional-grade analysis + tools for professional short-sellers. Subscribe to the newsletter: https://teapawt.net/t.co/rB45oOK51N

Joined February 2026
Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)Photo by ShortSide Research (@ShortSideIO)
📊Get the pre-market newsletter (free trial): shortsideresearch.github.io/… ✅Daily pre-market newsletters (7:30 AM + 9:15 AM EST) ✅End-of-day recap & accuracy report (4 PM EST) ✅Squeeze risk scores for all gappers ✅Catalyst & dilution analysis ✅Sector trend reports ✅Exclusive subscriber-only gappers ✅Monthly short thesis reports ✅Foreign security warnings ✅Nasdaq delist risk alerts
2,998
$DRTS +11% at $14.86 Pre-market watch. Squeeze 2/10 · WAIT FOR FAILURE · Foreign risk 9 months median follow-up, while Stock Titan references eight alive at cutoff; the encouraging but small early dataset makes catalyst-blind shorting unattractive.
147
$AIMD +11% at $1.37 Pre-market watch. Squeeze 7/10 · HTB · WAIT FOR FAILURE 1 million three-year ASE contract, giving shorts a real commercial narrative to respect.
70
$OPTT +12% at $0.36 Pre-market watch. Squeeze 4/10 · WAIT FOR FAILURE · Delist risk 50 per package; financing creates supply risk, but the warrant-inclusive price is not a standalone common-share valuation anchor.
58
$IMTE +13% at $0.41 Pre-market watch. Squeeze 4/10 · WAIT FOR FAILURE · Foreign risk · Delist risk No clear catalyst explains the gap.
43
$CRDF +15% at $0.84 Pre-market watch. Squeeze 3/10 · WAIT FOR FAILURE Cardiff's release carried by Yahoo Finance announces FDA Fast Track designation for onvansertib in first-line RAS-mutated metastatic colorectal cancer.
73
$GP +21% at $1.41 Pre-market watch. Squeeze 6/10 · WAIT FOR FAILURE · Foreign risk · Delist risk Stock Titan reports just 391.
74
$LXEO +23% at $3.53 Pre-market watch. Squeeze 3/10 · WAIT FOR FAILURE Lexeo's release carried by Yahoo Finance announces positive interim Phase I/II LX2020 data in PKP2 arrhythmogenic cardiomyopathy.
90
$GIPR +23% at $0.27 Pre-market watch. Squeeze 9/10 · HTB · SQUEEZE TRAP · Delist risk 3 million warrant exercise transaction, leaving shorts facing financing-related supply but severe microfloat squeeze risk.
85